Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
Sponsor: Kadmon, a Sanofi Company
Listed as NCT03203642, this PHASE2 trial focuses on ADPKD and Autosomal Dominant Polycystic Kidney and remains completed. Sponsored by Kadmon, a Sanofi Company, it has been updated 23 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
23 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Mar 2023 [monthly]
Completed PHASE2
▶ Show 18 earlier versions
-
Jun 2022 — Jul 2022 [monthly]
Completed PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Nov 2017 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kadmon, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .